




Jing Meng1, Yanrong Liu2, Jingxia Han1, Qiang Tan1, Shuang Chen2, Kailiang Qiao1, Honggang Zhou1,2,
Tao Sun1,2* and Cheng Yang1,2*
Abstract
Background: Vascular endothelial growth factor receptors (VEGFRs) are the major receptors involved in endothelial
cell-dependent tumor angiogenesis. There are studies account for the effects of Hsp90 on angiogenesis, but the
role and mechanism of Hsp90β isoforms and NVP-BEP800, a specific inhibitor of Hsp90β, in tumor angiogenesis is
rarely mentioned.
Methods: Immunohistochemistry and statistical analysis was used to evaluate the correlation between Hsp90β
expression, CD31 endothelial cell-dependent vessel density, and VEGFRs expression in tissue samples of 96 HCCs.
Kaplan-Meier survival analysis and COX proportional hazards analysis the relation of Hsp90β and prognosis. HUVEC
cells were transfected with Hsp90β or treated with NVP-BEP800, and then cell proliferation, migration, invasion
and tube formation were investigated. The VEGFR1 and VEGFR2 expression was determined by Western blot and
immunofluorescence. The VEGFR1 and VEGFR2 promoter activities were detected by dual luciferase report system.
In vivo, the angiogenesis promotion of Hsp90β and anti-angiogenesis efficacy of NVP-BEP800 was tested in HCC
xenograft models. Histological analysis was performed on tumor samples to evaluate Hsp90β, VEGFRs expression
and MVD.
Results: This study investigated the correlation between Hsp90β expression and CD31+ endothelial cell-dependent
vessel density. Hsp90β promoted VEGFRs expression by increasing their promoter activities. The proliferation,
migration, invasion, and tube formation activities of human endothelial cells significantly increased when Hsp90β
was overexpressed. NVP-BEP800 down-regulated VEGFRs expression to significantly reduce tubular differentiation,
as well as endothelial cell proliferation, migration, and invasion. Furthermore, NVP-BEP800 decreased VEGFR1 and
VEGFR2 promoter activities. In vivo, Hsp90β promoted VEGFRs and CD31 expression in human hepatocellular carcinoma
tumor xenografts and was associated with increased tumor microvessel density. After 18 days of treatment with
30 mg/kg/day NVP-BEP800, VEGFRs and CD31 expression significantly decreased.
Conclusion: Hsp90β induced endothelial cell-dependent tumor angiogenesis by activating VEGFRs transcription.
NVP-BEP800 has potential as a therapeutic strategy for inhibiting tumor angiogenesis by decreasing endothelial
cell progression and metastasis. It can help develop a therapeutic strategy for tumor treatment through the
inhibition of endothelial cell progression and metastasis.
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Background
Tumor initiation and malignant evolution are closely re-
lated to angiogenesis [1, 2]. A physiological or pathological
neovascularization process is necessary to initiate tumor
tissue ischemia, growth, or metastasis [3]. In angiogenesis,
endothelial cell proliferation and migration cause new capil-
laries to develop from preexisting capillaries [4]. In addition,
tumor cells, pericytes, immune cells, hematopoietic cells,
circulating endothelial progenitor cells, and various types of
molecules are also involved in the complicated process of
angiogenesis [5]. Angiogenesis involves complex signaling
pathways and many key regulatory factors, such as vascular
endothelial growth factor (VEGF)/vascular endothelial
growth factor receptor (VEGFR) [6–8], angiopoietins,
integrins, neuropilin-1, thrombospondin-1, vasohibin,
and NOTCH/delta-like protein 4 pathway [5]. Among
these pathways, the VEGF/VEGFR system of endothe-
lial cells is the classical pathway used in blood vessel
formation [9, 10]. The VEGF receptor family includes
VEGFR1, VEGFR2, and VEGFR3 [11]. The high affinity
of VEGF and VEGFR1, VEGFR2 induce proliferation,
migration and differentiation of vascular endothelial cells
[12]. Activated endothelial cells degrade the extracellular
matrix, subsequently form tubular structures, and recruite
supporting cells to form stable vessels [1, 13, 14]. There-
fore, VEGF/VEGFR is an crucial pathway in angiogenesis
of tumor.
Heat shock protein 90 (Hsp90) is a molecular
chaperone that is induced in response to cellular stress.
Hsp90 stabilizes client proteins involved in the cell cycle,
proliferation, migration, and apoptosis [15]. The Hsp90
family has four major members: Hsp90α, Hsp90β,
GRP94, and Hsp75. Evidence suggest that Hsp90 is im-
portant in regulating tumor angiogenesis. Hsp90, as a
key protein chaperone, plays an important role in the
PI-3 K/AKT/mTOR complex of the PI-3 K/AKT signaling
pathway, which promotes endothelial cell survival [16, 17].
VEGFR2 is also reported to be a client protein of Hsp90,
which can form a complex with human umbilical vein
endothelial cells (HUVEC) [18]. Furthermore, the Hsp90
inhibitor suppresses the expression of VEGFRs and
VEGFR complexes, such as integrins [19], focal adhesion
kinase (FAK), and neuropilin coreceptors [5]. Although
most studies account for the effects of Hsp90α isoforms
on angiogenesis, the role and mechanism of Hsp90β iso-
forms in tumor angiogenesis is rarely mentioned.
We have previously established that Hsp90β is associated
with the tumor malignancy of hepatocellular carcinomas
(HCCs). HCC is a highly vascular tumor, thus providing an
attractive target for the development of new anticancer
drugs is necessary [20]. In the present study, we evaluate
whether Hsp90β expression increased in HCCs with a high
degree of malignancy. Results showed that there was an
obvious relationship between Hsp90β expression and
endothelial cell-dependent vessel density. Hsp90β in-
creased VEGFRs expression by activating their pro-
moters and enhancing endothelial cell proliferation,
migration, and tubular structure formation. NVP-BEP800,
an Hsp90β inhibitor, decreased VEGFRs expression and
inhibited HCC tumor angiogenesis. Therefore, NVP-
BEP800 has potential as a therapeutic strategy for inhibiting
tumor angiogenesis by decreasing endothelial cell progres-
sion and metastasis.
Methods
Cell culture and transfections
HUVECs and PLC-PRF-5 cells were obtained from the
Cell Bank of Shanghai Institute for Biological Sciences
(Shanghai, China). HUVEC cells were cultured in
medium 199 (M-199) containing endothelial cell growth
supplement, 10% fetal bovine serum (FBS), and 1% anti-
biotics (100 U/mL penicillin and 10 μg/mL strepto-
mycin). PLC-PRF-5 cells were cultured in Roswell Park
Memorial Institute 1640 medium supplemented with
10% FBS and penicillin–streptomycin solution. All cells
were maintained at 37 °C in a 5% CO2 incubator. All the
plasmids were transfected into cells by Lipofectamine
2000 (Invitrogen, USA).
Luciferase activity assays
HUVECs were seeded in 96-well plates. After 24 h, the
plasmids, namely, pEZX–PG04–VEGFR1 and pEZX–
PG04–VEGFR2 (FulenGene, China), were either trans-
fected separately into cells, co-transfected with pcDNA3–
Hsp90β or pRNAT-U6-siHsp90β, or incubated with NVP-
BEP800 (Selleck, USA) for 48 h. Gaussia and secreted
alkaline phosphatase (SEAP) luciferase activities were
consecutively measured by a dual-luciferase reporter assay
system (FulenGene, China) after 48 h of transfection.
Gaussia luciferase activity was normalized to SEAP
activity.
Cell invasion assays
HUVECs in serum-free medium were seeded onto a
chamber coated with Matrigel (BD, USA) and inserted
into the wells of a 24-well plate. FBS was added to a 24-
well plate located below the chamber to serve as a
chemoattractant. After 24 h, invasive cells located on the
lower surface of the chamber were stained with 0.1%
crystal violet and counted.
Wound healing assay
HUVECs were seeded at 80% to 90% confluence in 24-
well plates. An area of cells was removed with a pipette
tip drawn across the center of each well. Cells were
washed thrice followed by treatment with FBS-free
medium containing DMSO or 2 μM NVP-BEP800. The
speed of wound closure was monitored after 16, 32, and
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48 h by comparing the wound distance ratio at 0 h. This
experiment was independently repeated thrice.
Tube formation assay
HUVECs were seeded onto a 48-well plate coated with
Matrigel (BD, USA) followed by treatment with a
medium containing DMSO or 2 μM NVP-BEP800. Peak
tube formation was observed at 12 h post-treatment.
Four random fields were observed under a microscope.
The number of tubes for each treatment was quantified.
This experiment was independently repeated thrice.
Western blot analysis
Cells were washed with phosphate-buffered saline (PBS)
and lysed in ice-cold lysis buffer containing protease in-
hibitor cocktail (Sigma) for 30 min. Lysates were separated
by electrophoresis and transferred onto polyvinylidene
difluoride membranes (Millipore; Bedford, MA, USA).
The membranes were blocked and incubated with the
primary antibodies of Hsp90β, VEGFR1, and VEGFR2
(CST, USA). The membranes were then incubated with a
goat anti-rabbit IgG–HRP secondary antibody (Thermo
Scientific, USA). GAPDH was used as the loading control.
Protein expression was assessed with enhanced chemilu-
minescent substrate (Millipore, USA) and by exposure to
chemiluminescent film.
Immunofluorescence
HUVECs were fixed with 3.7% formaldehyde in PBS for
5 min at room temperature and blocked with 1% bovine
serum albumin for 30 min. The cells were incubated
overnight at 4 °C with VEGFR1 antibody (1:200; CST,
USA) or VEGFR2 antibody (1:200, CST, USA), and then
incubated with FITC- and TRITC-labeled secondary anti-
bodies (Earthox LLC, USA) for 1 h at room temperature.
Each step was followed by two 5-min washes in PBS. The
prepared specimens were counterstained with DAPI
(Southern Biotechnology Associates Inc., USA) for 2 min
and observed with a confocal microscope (Nikon, Japan).
Immunohistochemistry assay and analysis
Paraffin sections of human samples and tumor tissue of
mice were deparaffinized in xylene and rehydrated in a
series of graded alcohols and antigen was retrieved in
0.01 M sodium citrate buffer. Samples were incubated
with 3% H2O2 for 10 min and then blocked in 1% bovine
serum albumin in PBS for 1 h. The slides were incubated
overnight at 4 °C with Hsp90β, VEGFR1, VEGFR2,
CD31 and Ki67 primary antibody. Using the known
positive section as the positive criteria, PBS displaces
primary antibody as negative criteria. The secondary
antibody was followed added with using HRP-Polymer
anti-Mouse/Rabbit IHC Kit (Maixin Biotech, China) for
1 h at room temperature. Then, samples were developed
with diaminobezidine (Vector Laboratories) reagent and
counterstained with hematoxylin and mounted with per-
mount [21].
ImageJ software was used to quantify the MVD based
on CD31 staining. The percentage of positively stained
area was calculated by using a color deconvolution for
separating the staining components (diaminobezidine
and hematoxylin) in at least six fields per each sections
[21]. The results were presented as percentage of treated
group compared to control one. All sections were ana-
lyzed and evaluated independently by two pathologists
(T.S. and Y.R.L.) at double blinded, and the results were
reconfirmed once inconsistent.
Xenograft tumor model
Approximately 1 × 106 PLC or PLC-Hsp90β cells were
injected subcutaneously into the middorsal region of
each BALB/c nude mouse. Each group (Control, Hsp90β
and NVP-BEP800 group) consisted of eight mice.
Tumor-bearing mice began to receive treatment at the
time point when the average tumor size reached 100-
200 mm3. NVP-BEP800 was formulated as a suspension
in 0.5% methylcellulose and was given at the dose of
30 mg/kg per day by intragastric administration for
18 days [22]. Solvent buffer at the same volume was
used in control and Hsp90β groups. Tumor sizes were
measured every 2 days using a caliper and calculated ac-
cording to a standard formula (length × width2 × 0.52) as
previously described [23].
Patient samples
HCC tissue microarrays containing 96 cases were pur-
chased from US Biomax for IHC. Tissue blocks of the tis-
sue array were collected within 5 years. Each single tissue
spot on every array slide was individually examined by
certified pathologists according to the WHO published
standardizations for diagnosis, classification and patho-
logical grade. Both the hospital and the individual con-
sented for each specimen from clinical patients to be
included. All tissues were collected under the highest
ethical standards; the donor was completely informed and
provided consent. All human tissues are collected under
HIPPA-approved protocols.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism 6 and SPSS v. 19. Statistically significant differences
were calculated by student’s t-test, Wilcoxon rank-sum
test, Mann–Whitney U test, and Pearson’s correlation
as appropriate. Values of p < 0.05 were considered
significant.
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Results
Hsp90β was associated with HCC angiogenesis
Our previous study confirmed that Hsp90β was closely re-
lated to the metastasis and recurrence of HCC. Based on
the immunohistochemical (IHC) analysis of 96 HCC cases,
the expression level of Hsp90β and angiogenesis were
higher in HCC with a high degree of malignancy than in
HCC with a low degree of malignancy (Fig. 1a). The ex-
pression of CD31, a surface marker of neovascular endo-
thelial cells, was detected by immunohistochemical staining
of HCC tissues in different stages. Then, microvessel dens-
ity (MVD) was calculated (Fig. 1b). Pearson correlation and
linear regression anaysis showed that the levels of steady
state expression of the mRNA of Hsp90β and CD31 was
positively correlated (Additional file 1 Fig. S1a). We further
analyzed the correlation between Hsp90β expression and
MVD. The results showed that Hsp90β was positively cor-
related with MVD in HCC (P = 0.027) (Fig. 1c).
Hsp90β indicated poor prognosis
Kaplan–Meier survival analysis revealed that patients
with high levels of Hsp90β expression had significantly
lower overall survival (OS) compared with those with
low Hsp90β expression (P = 0.000) (Fig. 2a). Cox propor-
tional hazards model analysis was performed on the
basis of clinicopathological factors, Hsp90β expression
(high/low), and MVD presence (positive/negative).
Multivariate analysis showed that high Hsp90β expres-
sion, MVD, advanced clinical stage, and histological dif-
ferentiation were indicators of poor prognosis (P = 0.018,
0.047, 0.022, and 0.009, respectively) (Fig. 2b).
Correlation between Hsp90β and EGFRs
We analyzed 96 liver cancer cases and found that the
expression levels of Hsp90β, VEGFR1, and VEGFR2
in liver tumor tissues were correlated with the patho-
logical grade and clinical stage of the tumor (Table 1).
Immunohistochemical staining showed that HCC pa-
tients with high Hsp90β expression levels also highly
expressed VEGFR1 and VEGFR2. Additionally, VEGFR1
and VEGFR2 expression levels were higher in the endo-
thelial cells surrounding vessels (Fig. 3a). Correlation ana-
lysis showed that Hsp90β was associated with VEGFR1
and VEGFR2 expression (P = 0.022 and P = 0.035, res-
pectively) (Fig. 3b). The correlation studies of Hsp90β and
VEGFR1, VEGFR2 mRNA levels were consistent with
those of IHC evaluation (Additional file 1 Fig. S1b, c).
Hsp90β stimulated endotheliocytes to proliferate and
accelerate neovascularization depending on VEGFR
expression
VEGFRs are major receptors on endothelial cells that
are involved in multiple signaling pathways, including
the induction of mitogenesis, migration, invasion, and
differentiation in neoangiogenesis [24]. Sanderson et al.
[18] reported that VEGFR2 is a client protein of Hsp90
and they can form a complex in HUVECs to promote
endothelial cell migration; they also reported that
VEGFR2 deletion mutants are unable to associate with
Hsp90 [19, 25]. To elucidate the underlying mechanism
of Hsp90β in inducing angiogenesis, we evaluated the
effects of Hsp90β on VEGFRs expression. Our results
showed that as with VEGF treated HUVEC cells,
VEGFR1 and VEGFR2 expression levels also increased
after Hsp90β overexpression (Fig. 4a). This result was
validated by immunofluorescence staining (Fig. 4b).
Whereas, VEGFR1 and VEGFR2 expression levels de-
creased after Hsp90β knocked down. When the HUVEC
cells simultaneously treated with siHsp90β and VEGF,
VEGFR1 and VEGFR2 expression levels increased
Fig. 1 Correlation between Hsp90β and MVD. a Representative images of IHC staining for Hsp90β in tissue microarrays of human HCC at different
stages (left, stage I; right, stage IV) showed weak expression in primary cancer tissues (stage I) and strong expression in metastatic tissues (stage IV).
Black arrows point to microvessels. b MVD measured by immunostaining for CD31 in HCC tissue microarrays. MVD was higher in the Hsp90β-positive
group than in the Hsp90β-negative group. Black arrows point to microvessels. c MVD and Hsp90β-positive stainings were quantified and the correlation
was analyzed with Spearman correlation method (correlation coefficient: R = 0.226, P = 0.027)
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compared with alone Hsp90β knocked down group
(Fig. 4a). Furthermore, we used a dual-luciferase report
system to determine the effect of Hsp90β on the pro-
moter activities of VEGFR1 and VEGFR2. The results
showed that Hsp90β and/or VEGF increased VEGFR1
and VEGFR2 promoter activities, Hsp90β knockdown
decreased VEGFR1 and VEGFR2 promoter activities and
VEGF released the inhibition effect of Hsp90β knocked
down on VEGFRs promoter activities (Fig. 4c). In
addition, Hsp90β promoted HUVEC proliferation and
Hsp90β knockdown inhibited HUVEC proliferation.
VEGF treatment counteracted the inhibitory effect of
knocked down Hsp90β (Fig. 4d). Then, we performed
Transwell chamber (with or without Matrigel on the fil-
ters) invasion and migration assays to examine the effects
of Hsp90β on HUVEC invasion and migration. The num-
ber of HUVECs that migrated through the filters showed
that cell invasion and migration significantly increased
after Hsp90β overexpression and/or VEGF treatment. The
cell invasion and migration decreased obviously when
Hsp90β knocked down and VEGF released the inhibition
effect of knocked down Hsp90β (Fig. 4e and f).
In vitro, endothelial cells can form a three-dimensional
tube in Matrigel culture. To examine the effects of
Hsp90β on HUVEC tube formation, we seeded HUVECs
that were transfected with Hsp90β, Hsp90β siRNA, and/
or treated with VEGF for 48 h on Matrigel. The results
showed that Hsp90β significantly enhanced HUVEC
tube formation, whereas Hsp90β silencing inhibited
HUVEC tube formation. VEGF increased the effect of
Hsp90β on angiogenesis and knockdown of Hsp90β
obviously decreased VEGF-induced tube formation
(Fig. 4g). Our results showed that Hsp90β affected in
vitro VEGFRs promoter activities, VEGFRs expression,
and HUVEC proliferation, migration, invasion, tube
formation, and angiogenesis.
Fig. 2 Relationship between Hsp90β and prognosis. a Kaplan–Meier curves for the OS of HCC patients with Hsp90β-positive and Hsp90β-negative
expression. The Hsp90β-negative group tended to have a longer survival time than the Hsp90β-positive group (P = 0.027). b Multivariate analyses of
factors influencing survival. Cox proportional hazard model analysis was performed with clinicopathological factors (clinical stage, P = 0.022; histological
differentiation, P = 0.009), Hsp90β expression (positive/negative, P = 0.018), and MVD (positive/negative, P = 0.047)
Table 1 Correlation between Hsp90β, VEGFR1, VEGFR2, and primary tumor characteristics
Variant Hsp90β X2 P VEGFR1 X2 P VEGFR2 X2 P
Low High Low High Low High
Age (year)
≤60 204 53 0.001 0.973 67 12 0.701 0.403 60 19 0.918 0.338
>60 39 10 13 4 11 6
Sex
M 202 58 3.128 0.077 74 13 1.986 0.159 64 23 0.075 0.784
F 41 5 6 3 7 2
Histological differentiation
≤II 180 38 4.621 0.032* 62 16 4.431 0.035* 61 17 3.895 0.048*
>II 63 25 18 0 10 8
Stage
≤II 148 47 4.061 0.044* 46 14 5.120 0.024* 48 12 3.032 0.082
>II 95 16 34 2 23 13
*Significantly different, P <0.05
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Hsp90 inhibitor blocked the proliferation, migration,
invasion, and tube formation of endothelial cells
The ability of Hsp90 inhibitors, such as geldanamycin
and its derivatives, to suppress endothelial cell prolifera-
tion has been previously described [26]. However, the
effect of NVP-BEP800, a new Hsp90 inhibitor, on endo-
thelial cells has not been reported. To determine the
direct cytotoxic effects of NVP-BEP800 on endothelial
cells, we conducted an in vitro cytotoxicity experiment.
The different concentrations of NVP-BEP800 were cyto-
toxic to HUVECs when given as a treatment for 48 h
(Fig. 5a). In addition, the toxicity of NVP-BEP800 in
normal human liver cells (HHL-5) and various HCC cell
lines (SMMC-7721, PLC-PRF-5, BEL-7402) were also
measured. The results showed that NVP-BEP800 has no
significant toxicity in HHL-5, and inhibited the prolifera-
tion of HCCs (Additional file 2 Fig. S2). HUVECs in log-
phase growth were measured over 72 h and showed that
NVP-BEP800 (2 μM) inhibited the proliferation of hu-
man endothelial cells (Fig. 5b). There was no obvious ef-
fect on death and apoptosis of HUVECs under 2 μM
NVP-BEP800 treatment for 48 h (Additional file 3 Fig.
S3). Western blot analysis showed that VEGFR1 and
VEGFR2 expressions decreased under 48 h of 2 μM NVP-
BEP800 treatment (Fig. 5c). Furthermore, we analyzed the
effect of NVP-BEP800 on VEGFRs promoter activities.
The results of the dual-luciferase reporter assay showed
that NVP-BEP800 significantly decreased VEGFR1 and
VEGFR2 promoter activities (Fig. 5d). In addition, a
scratch wound assay showed that Hsp90 inhibitors pre-
vented HUVEC haptotaxis. Control cells completed
wound closure after 48 h. By contrast, cells treated with
2 μM NVP-BEP800 failed to complete wound closure
within 48 h (Fig. 5e). To test the effect of NVP-BEP800 in-
hibition on HUVEC tube formation, HUVECs were
treated with 2 μM NVP-BEP800 for 24 h and then seeded
on Matrigel for 12 h. The results showed that NVP-
BEP800 significantly decreased tube formation compared
with control cells (Fig. 5f). We evaluated the tube forma-
tion in HUVECs that knocked down Hsp90α or Hsp90β
under NVP-BEP800 treatment. The results showed that
compared to Hsp90α knocked down group, the tube for-
mation in siHsp90α+NVP-BEP800 group were signifi-
cantly reduced. While there was no statistically significant
difference in Hsp90β knocked down group and
siHsp90β+NVP-BEP800 group (Additonal file 4 Fig. S4).
It is indicated that the inhibition of endothelial cell-
dependent tumor angiogenesis of NVP-BEP800 was
Fig. 3 VEGFR1 and VEGFR2 expression in Hsp90β-negative (Hsp90β-) and Hsp90β-positive (Hsp90β+) HCC tissues. a a and c, VEGFR1 and VEGFR2
expression in Hsp90β- HHC group; b and d, VEGFR1 and VEGFR2 expression in Hsp90β + HCC group (original magnification × 400). Black arrows
point to microvessels. b Correlation analysis between Hsp90β and VEGFR1 (P = 0.022) and VEGFR2 (P = 0.035)
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primarily by inhibiting the activity of Hsp90β. In addition,
17-Allylamino-17-demethoxygeldanamycin (17-AAG) were
compared with NVP BEP800 on the proliferation and tube
formation of HUVECs (Additonal file 5 Fig. S5). The re-
sults showed that 17-AAG inhibited cell proliferation,
while the inhibition effect of NVP-BEP800 was stronger
than 17-AAG on tube formation.
Hsp90β promoted angiogenesis and Hsp90 inhibitor
suppressed angiogenesis in vivo
We demonstrated that Hsp90β promoted endothelial
cell proliferation, migration, and tube formation and that
the Hsp90 inhibitor attenuated VEGFR levels and inhib-
ited tube formation in vitro. Then, we constructed a
nude mice subskin model that was transplanted with hu-
man liver cancer. Control group mice subcutaneously
received PLC cell suspensions. Hsp90β group mice sub-
cutaneously received a suspension of PLC cells trans-
fected with pcDNA-Hsp90β plasmids. NVP-BEP800
group mice subcutaneously received a suspension of
PLC cells. When the tumors volume reached 100-
200 mm3, NVP-BEP800 group mice were treated with
NVP-BEP800 (30 mg/kg/daily) by intragastric adminis-
tration for 18 days and solvent buffer at the same
Fig. 4 Hsp90β promotes endotheliocyte proliferation and accelerates neovascularization. a Western blot analysis showed VEGFR1 and VEGFR2
expression levels in HUVEC cells overexpressed or knocked down Hsp90β and/or under VEGF treatment. b Immunofluorescence of VEGFR1 and
VEGFR2 expression in HUVEC cells overexpressed Hsp90β alone, VEGF treatment alone or overexpressed Hsp90β under VEGF treatment. c HUVEC
cells were transiently transfected with VEGFR1- or VEGFR2- dependent reporter gene plasmids. Luciferase activity was measured when cells
overexpressed or knocked down Hsp90β and/or under VEGF treatment. d Growth curve of HUVEC cells overexpressed or knocked down Hsp90β and/or
under VEGF treatment, measured by SRB assay. (*, vs control group, P< 0.05; #, vs VEGF group, P< 0.05;▲, vs Hsp90β group, P< 0.05; ■, vs siHsp90β
group, P< 0.05) e Transwell assays indicated invasion ability when HUVEC cells overexpressed or knocked down Hsp90β and/or under VEGF treatment. f
Migration ability increased when HUVEC cells overexpressed or knocked down Hsp90β and/or under VEGF treatment. g In vitro assay for vascular
mimicry of HUVEC cells in three-dimensional culture at 12 h. a, Representative graphs; black arrows point to tubes. b, Tube formation quantification was
analyzed after HUVEC cells overexpressed or knocked down Hsp90β and/or under VEGF treatment. *P< 0.05, **P< 0.01
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volume was used in control and Hsp90β groups. The re-
sults showed that compared with the control group,
Hsp90β promoted the liver tumor growth, and NVP-
BEP800 inhibited tumor growth in vivo (Fig. 6a, b). To
further check the effect of Hsp90β and NVP-BEP800 on
cell proliferation, immunohistochemical analysis of Ki67
was performed with the tumor issues (Fig. c, d). Also, we
demonstrated that VGFR1 and VEGFR2 expression levels
increased in cells overexpressing Hsp90β, but decreased
after NVP-BEP800 treatment (Fig. 6e, f ). Immunohisto-
chemical detection revealed that CD31 expression and
MVD in the Hsp90β-overexpressing group were signifi-
cantly higher than those in the control group, but de-
creased in the presence of NVP-BEP800 (Fig. 6g, h).
There was no significant difference about blood vessel tis-
sue between control and NVP-BEP800 group by analysis
mice liver and lungpathological sectionusinghematoxylin and
eosin staining (Additonal file 6 Fig. S6). Our data suggested
that Hsp90β contributed to endothelial cell-dependent
angiogenesis.
Discussion
Angiogenesis is critical to tumor growth, invasion, and
metastasis, especially during the early stages of tumor
development. Our previous work demonstrated that
Hsp90β is a marker protein for detecting liver cancer
malignancy. Based on the analysis of 96 liver cancer
cases, we demonstrated that Hsp90β was up-regulated in
HCCs with a high degree of malignancy. Especially, in
HCC tissues, Hsp90β expression in vascular endothelial
cells also significantly increased. We examined CD31-
positive endothelial cell-dependent vascular density and
found that Hsp90β expression was positively correlated
with MVD. The survival time of Hsp90β-negative HCC
patients was longer than that of Hsp90β-positive HCC
patients. Cox regression analysis showed that Hsp90β
expression and MVD, as well as the clinical stage and
pathological grade of the tumor, are risk factors that de-
termine the survival of HCC patients. Furthermore, we
found that VEGFRs were highly expressed in HCC tis-
sues with high Hsp90β expression in endothelial cells.
Fig. 5 NVP-BEP800 inhibited endothelial cell proliferation, migration, invasion, and tube formation. a Incubation with different concentrations of
NVP-BEP800 for 48 h inhibited HUVEC cell proliferation. b Growth curve of HUVEC cells incubated with 2 μM NVP-BEP800, as measured by SRB
assay. c Western blot analysis showed that treatment with 2 μM NVP-BEP800 down-regulated VEGFR1 and VEGFR2 expression in HUVEC cells. d HUVEC
cells were transiently transfected with VEGFR1- or VEGFR2- dependent reporter gene plasmids and treated with 2 μM NVP-BEP800. After 24 h, the cells
were lysed and luciferase activity was measured. e The wound healing ability of HUVEC cells was assessed after 48 h of NVP-BEP800 treatment. DMSO
treatment was used as the standardized control for quantification. f In vitro assay for vascular mimicry of HUVEC cells treated with NVP-BEP800 for 48 h
in three-dimensional culture. NVP-BEP800 inhibited cord formation of HUVEC cells. *P < 0.05, **P < 0.01
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Statistical analysis showed that Hsp90β expression was
correlated with VEGFRs.
In vitro, Hsp90β promoted VEGFR1 and VEGFR2 pro-
moter activities. Furthermore, Hsp90β promoted VEGFR
expression in endothelial cells. VEGFRs are crucial to
tumor angiogenesis, promote the proliferation of endo-
thelial cells, and increase vascular permeability [27]. The
stimulating effect of Hsp90β was more obvious on
VEGFR2 promoter activity than on VEGFR1 promoter
activity, which indicated that Hsp90β mainly acts on
VEGFR2. After Hsp90β overexpression, endothelial cell
proliferation, invasion, migration, and tubular structure
formation increased. The promoting effect was more ap-
parent when VEGF treatment was simultaneously per-
formed. This may be due to Hsp90β promoting VEGFRs
expression by stimulating VEGFRs promoter activities,
and after VEGF treatment, more receptors were induced
to combine with VEGF and lead to active a series of
downstream pathways. Hsp90β knockdown decreased
the ability of endothelial cells to form tube structures.
Tube formation of simultaneous Hsp90β knockdown
and VEGF treatment group was decreased obviously
compared with the VEGF-only treated group. This finding
indicated that knocked-down Hsp90β counteracted the
tube formation induced by VEGF. Compared with Hsp90β
knockdown group, the simultaneous Hsp90β knockdown
and VEGF treatment group had increased tube formation.
This finding indicated that VEGF can release the inhibi-
tion caused by Hsp90β knockdown in HUVEC cells. Also,
it means that VEGF can release the inhibition on
Fig. 6 Immunohistochemical analysis of VEGFRs expression and tumor vascularization in a HCC xenograft model. a Control group mice subcutaneously
received PLC cell suspensions. Hsp90β group mice subcutaneously received a suspension of PLC cells transfected with pcDNA-Hsp90β
plasmids. NVP-BEP800 group mice subcutaneously received a suspension of PLC cells and were treated by intragastric administration with
NVP-BEP800 (30 mg/kg/day). b Tumor sizes were measured every 2 days and tumor volumes were calculated. c, d To check the effect of
Hsp90β and NVP-BEP800 on cell proliferation, immunohistochemical analysis of Ki67 was performed with the tumor issues. The intensity of
Ki67-positive cell was calculated with Image J software. e, f VEGFR1 and VEGFR2 expression in tumor tissue of the control group, Hsp90β
group, and NVP-BEP800 group mice. g, h Analysis of MVD based on CD31 staining of tumor tissue by Image J software showed that vessel
number significantly increased in the Hsp90β group and that vessel number decreased in the NVP-BEP800 group. *P < 0.05, **P < 0.01
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angiogenesis caused by Hsp90β knockdown. Intratumoral
MVD and VEGFRs expression increased in the nude mice
that were subcutaneously tumor burdened with Hsp90β-
overexpressing HCC cells.
Based on the role of Hsp90β in angiogenesis, we
sought to identify Hsp90β inhibitors as antitumor agents
by anti-angiogenesis. Hsp90 inhibitors, such as NVP-
AUY922 [28], VER49009/VER50589 [29], and geldana-
mycin derivatives, including 17-AAG and 17-DMAG
[26, 30–32], are used as antitumor and antiangiogenesis
drugs. The direct effect of NVP-BEP800, a new Hsp90β
inhibitor, on anti endothelial cell-dependent angiogenesis
has never been reported. The antiangiogenic activities of
Hsp90β inhibitors directly affected endothelial cells. NVP-
BEP800 inhibited vascular endothelial cell proliferation.
This inhibitory effect was dose-dependent. Endothelial cell
migration, invasion, and tube formation directly affected
the angiogenic process. There was reported that Hsp90
forms a complex with VEGFR2, but VEGFR2 deletion mu-
tants cannot associate with Hsp90 [19, 25]. Interestingly,
our findings showed that NVP-BEP800 decreased VEGFR1
and VEGFR2 expression levels by inhibiting VEGFR1 and
VEGFR2 promoter activities. Our in vitro studies indicated
that tumors in mice treated with NVP-BEP800 showed de-
creased VEGFRs expression and reduced microvascular
density. In addition, no significant difference in the blood
vessel tissues of liver and lung was observed between the
normal and NVP-BEP800 treated mice. So we hold that
the NVP-BEP800 may only affect the tumor neovasculari-
zation process and may have no significant effect on the
blood vessels of the normal tissues.
In conclusion, our data illustrated that Hsp90β promoted
endothelial cell-dependent tumor angiogenesis by increas-
ing VEGFRs expression. Moreover, NVP-BEP800, a Hsp90
inhibitor, exerted antiangiogenic activity when administered
orally. Moreover, it is reported that NVP-BEP800 used as
an antineoplastic agent, via decreasing Hsp90 client pro-
teins of downstream [22]. Therefore, Hsp90 inhibitors may
target multiple pivotal points in both tumor and endothelial
cell survival, proliferation, and invasion to provide a
combinatorial approach to attack multiple features of
malignant phenotypes [18]. Hsp90 inhibitors may be
used as a therapeutic strategy to inhibit tumor angio-
genesis by decreasing endothelial cell progression and
metastasis.
Conclusions
Hsp90β induced endothelial cell-dependent tumor angio-
genesis by activating VEGFRs transcription. We provided
new insight into the regulatory mechanism of tumor
angiogenesis by exploring the role of Hsp90β, which may
also help develop a therapeutic strategy for tumor treat-
ment through the inhibition of endothelial cell progres-
sion and metastasis.
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